熱門資訊> 正文
ARS Pharma获得2.5亿美元贷款以加速Neffy的推出
2025-09-30 04:19
- ARS Pharmaceuticals (NASDAQ:SPRY) announced a $250M senior secured term loan with affiliates of RA Capital and OMERS Life Sciences.
- An initial $100M draw will support the commercial expansion of neffy, its needle-free epinephrine nasal spray.
- Funds will also back marketing and medical efforts to build real-world evidence of neffy's effectiveness, aligning it with traditional epinephrine injections.
- Source: Press release
More on ARS Pharmaceuticals
- ARS Pharmaceuticals: A Significant Upside Is Expected From neffy
- ARS Pharmaceuticals, Inc. (SPRY) Q2 2025 Earnings Call Transcript
- ARS Pharmaceuticals: High Risk High Reward Rollout Of No Needle Epinephrine
- ARS Pharma rises after Japan nod for neffy nasal spray for allergy
- ARS Pharma drops 9% as Lupin files application for generic neffy
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
